Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.
We have developed a new class of platinum complex [Pt(trans-l-dach)(1,3-bis(phosphino)propane)] dinitrate (KHPC-001) with potent antitumor activity and low nephrotoxicity, confirmed in vitro and compared in vivo with cisplatin, KHPC-001 or cisplatin was intraperitoneally injected on days 1, 5, and 9 into P388-bearing mice and the antitumor effects were compared. In vitro cytotoxicity, Pt accumulation, and DNA cross-link index were measured in P388 and LLC-PK1 cells after treatment with KHPC-001 or cisplatin. Twenty mg/kg (below one-tenth of LD50) of KHPC-001 had stronger antitumor effects than 2 mg/kg (about one-fifth of LD50) of cisplatin and cured 2 out of 6 mice without any toxicity. While the cytotoxicity of KHPC-001 and cisplatin were similar on P388 mouse leukemia cells, this new compound was much less cytotoxic to a kidney-derived line, LLC-PK1. This lower toxicity on the kidney cells was based on its low accumulation, causing less DNA crosslinking. KHPC-001 is a unique third-generation platinum complex with potent antitumor activity and low nephrotoxicity.